Skip to main content
38 search results for:

CDK inhibitors 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. play
    29-09-2020 | ESMO 2020 | Conference coverage | Video

    monarchE and PALLAS: A tale of two CDK4/6 inhibitors

    George Sledge Jr speculates on the reasons for the contrasting results of the monarchE and PALLAS trials of adjuvant abemaciclib and palbociclib, respectively, in hormone receptor-positive, early-stage breast cancer.

  2. 02-06-2020 | ASCO 2020 | News | Article

    BYLieve suggests alpelisib–fulvestrant benefit after progression on CDK inhibitors

    ASCO 2020 news: BYLieve points to the potential of alpelisib–fulvestrant in patients with HR-positive, HER2-negative breast cancer post-CDK inhibitor

  3. 02-04-2019 | Advanced breast cancer | Editorial | Article

    The use of CDK4/6-inhibitors in advanced, hormone-receptor positive breast cancer: why, when and who?

    CDK4/6 inhibitors are a valuable addition to the treatment armamentarium for HR-positive, HER2-negative advanced breast cancer, but questions about their use remain. The research team behind the Dutch Sonia study explores some of the most pressing questions.

  4. 27-07-2018 | Advanced breast cancer | Article

    CDK4/6 inhibitors in advanced hormone receptor-positive/HER2-negative breast cancer: a systematic review and meta-analysis of randomized trials

    Messina C et al. Breast Cancer Res Treat 2018; 172: 9. doi:10.1007/s10549-018-4901-0

  5. 20-11-2018 | Advanced breast cancer | Article

    Selecting the optimal position of CDK4/6 inhibitors in hormone receptor-positive advanced breast cancer – the SONIA study: study protocol for a randomized controlled trial

    van Ommen-Nijhof A et al.  BMC Cancer 2018; 18:1146. doi:10.1186/s12885-018-4978-1

  6. 05-06-2023 | Breast cancer | Conference coverage | Article
    ASCO 2023

    Adjuvant ribociclib reduces recurrence risk in early breast cancer

    He added that these findings “support ribociclib and nonsteroidal aromatase inhibitors as a new treatment of choice in a broad population – broader than we’ve seen before – of patients with stage II and stage III disease.”

  7. 08-12-2022 | SABCS 2022 | Conference coverage | Article

    First-line ribociclib plus ET RIGHT Choice for aggressive advanced breast cancer

    She continued: “We don’t use a lot of chemotherapy nowadays because of how well these CDK4/6 inhibitors work, but I think the little that we use is probably now dead.”

  8. 08-12-2022 | SABCS 2022 | Conference coverage | Article

    monarchE 4-year results show abemaciclib benefit is maintained beyond treatment completion

    The 4-year results from monarchE indicate that the invasive disease-free survival gain offered by adjuvant abemaciclib in people with high-risk, hormone receptor-positive, HER2-negative, early breast cancer is maintained even after the 2-year treatment period.

  9. 10-09-2022 | ESMO 2022 | Conference coverage | Article

    MONARCH 3: OS ‘numerically favors’ abemaciclib combination therapy

    Updated findings from the MONARCH 3 trial show a nonsignificant overall survival gain with the addition of abemaciclib to a first-line nonsteroidal aromatase inhibitor in postmenopausal patients with hormone receptor-positive, HER2-negative advanced breast cancer.

  10. 10-09-2022 | ESMO 2022 | Conference coverage | Article

    DAWNA-2 supports first-line dalpiciclib combo for advanced hormone receptor-positive breast cancer

    Dalpiciclib given in combination with an aromatase inhibitor offers a novel first-line treatment option for patients with locally advanced or metastatic hormone receptor-positive, HER2-negative breast cancer, say the DAWNA-2 investigators.

  11. 06-07-2022 | Breast cancer | News | Article

    Real-world data magnify abemaciclib–thrombosis link in breast cancer

    They add: “Our findings are particularly important because abemaciclib has recently become the first and only CDK 4/6 inhibitor to date to be approved for use beyond the metastatic disease setting.” medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2022 Springer Healthcare Ltd, part of the Springer Nature Group Cancer 2022; doi:10.1002/cncr.34367

  12. 05-06-2022 | ASCO 2022 | Conference coverage | Article

    Ribociclib plus endocrine therapy switch benefits CDK4/6 progressors

    Patients with metastatic breast cancer who progress during combination treatment with a CDK4/6 inhibitor and endocrine therapy may benefit from switching endocrine therapy and combining it with ribociclib, MAINTAIN study findings indicate.

  13. 05-06-2022 | ASCO 2022 | Conference coverage | Article

    Survival benefits unclear for add-on palbociclib in advanced breast cancer

    PALOMA-2 study findings suggest that first-line palbociclib does not improve overall survival when added to letrozole for estrogen receptor-positive, HER2-negative advanced breast cancer, but the analysis was hindered by missing data.

  14. 06-05-2022 | ESMO Breast 2022 | Conference coverage | Article
    News in brief

    Ribociclib plus fulvestrant OS gain for advanced breast cancer continues after 5 years

    Exploratory analyses from the MONALEESA-3 trial after more than 5 years of follow-up show that first-line use of ribociclib alongside fulvestrant continues to offers a significant overall survival benefit versus fulvestrant alone in patients with hormone receptor-positive, HER2-negative advanced breast cancer.

  15. 01-03-2022 | EMA | News | Article
    approvalsWatch

    EMA recommends extension of abemaciclib indication

    Read about this breast cancer decision here

  16. 15-02-2022 | Mesothelioma | News | Article

    MiST2 points to potential of abemaciclib in malignant mesothelioma

    A phase 2 trial has demonstrated promising antitumor activity and manageable toxicity of abemaciclib in previously treated patients with p16ink4A-negative malignant mesothelioma.

  17. 09-02-2022 | COVID-19 | News | Article
    News in brief

    PALLAS data provide reassurance on CDK4/6 inhibitor use during COVID-19 pandemic

    An analysis of the phase 3 PALLAS trial has shown no significant increase in SARS-CoV-2 test positivity and symptomatic infection with the adjuvant use of the CDK4/6 inhibitor palbociclib alongside endocrine therapy in patients with early breast cancer.

  18. 15-10-2021 | FDA | News | Article
    approvalsWatch

    Adjuvant abemaciclib gets go-ahead from FDA for early breast cancer

    Click here for more details on this approval

  19. 17-08-2021 | Adis Journal Club | Article
    Clinical Drug Investigation

    Is Molecular Tailored-Therapy Changing the Paradigm for CNS Metastases in Breast Cancer?

    In addition, there are several promising agents under investigation for patients with triple-negative brain metastases (third-generation taxane, etirinotecan, sacituzumab, immune-checkpoint inhibitors) and hormone receptor-positive brain metastases (CDK 4/5, phosphoinositide-3-kinase-mammalian target of rapamycin [PI3K/mTOR] inhibitors).

  20. 06-06-2021 | ASCO 2021 | Conference coverage | Article

    DAWNA-1 brings new CDK4/6 inhibitor into HR-positive advanced breast cancer space

    These hematologic toxicities are “consistent with the known class effects of CDK4/6 inhibitors,” Xu pointed out, additionally noting that none of the cases of neutropenia led to discontinuation of dalpiciclib and there were no cases of febrile neutropenia. medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2021 Springer Healthcare Ltd, part of the Springer Nature Group 2021 ASCO Annual Meeting; 4–8 June

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.